En el año 2001, el National Cholesterol Education Program-Adult Treatment Panel-III (NCEP ATP III) publicó su tercer informe para la detección, evaluación y tratamiento de la hipercolesterolemia. Desde entonces se han publicado varios estudios relacionados con nuevas estrategias de tratamiento. Algunos de ellos, centrados en los valores de colesterol unido a lipoproteínas de baja densidad (cLDL), han dado resultados que obligan a replantear los objetivos determinados hasta ahora. Y es que los resultados sugieren que la terapia hipolipemiante debería ser más intensa y buscar mayores reducciones del cLDL. En general, las nuevas orientaciones afectan a los subgrupos de alto riesgo, lo que ha motivado que se planteen valores de cLDL tan bajos que hasta hace poco eran inimaginables. No obstante, aún hay bastantes incertidumbres que deberán resolverse en los próximos años, incluido el valor inferior de cLDL que se debe conseguir para una prevención más efectiva.
Palabras clave
Ensayos clínicos
Colesterol
Lipoproteínas
Enfermedad coronaria
Este artículo solo puede leerse en
pdf
Bibliografía
[1.]
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
[2.]
A.M. Ross, T.G. Ganiats.
Results of new statin trials: should the low-density lipoprotein cholesterol treatment guidelines be revised?.
Curr Atheroscler Rep, (2005), 7 pp. 11-16
[3.]
Heart Protection Study Collaborative Group.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial.
Lancet, (2002), 360 pp. 7-22
[4.]
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
JAMA, (2002), 288 pp. 2998-3007
[5.]
C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, et al.
Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
N Engl J Med, (2004), 350 pp. 1495-1504
[6.]
H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A. Neil, S.J. Livingstone, CARDS investigators, et al.
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
Lancet, (2004), 364 pp. 685-696
[7.]
J.C. LaRosa, S.M. Grundy, D.D. Waters, C. Shear, P. Barter, J.C. Fruchart, Treating to New Targets (TNT) Investigators, et al.
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
N Engl J Med, (2005), 352 pp. 1425-1435
[8.]
T.R. Pedersen, O. Faergeman, J.J. Kastelein, A.G. Olsson, M.J. Tikkanen, I. Holme, et al.
Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial.
JAMA, (2005), 294 pp. 2437-2445
[9.]
S.E. Nissen, E.M. Tuzcu, P. Schoenhagen, B.G. Brown, P. Ganz, R.A. Vogel, REVERSAL Investigators, et al.
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
JAMA, (2004), 291 pp. 1071-1080
[10.]
A.J. Taylor, S.M. Kent, P.J. Flaherty, L.C. Coyle, T.T. Markwood, M.N. Vernalis.
ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness.
Circulation, (2002), 106 pp. 2055-2060
[11.]
T.J. Smilde, S. van Wissen, H. Wollersheim, M.D. Trip, J.J. Kastelein, A.F. Stalenhoef.
Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.
Lancet, (2001), 357 pp. 577-581
[12.]
S.M. Grundy, J.I. Cleeman, C.N. Merz, H.B. Brewer Jr, L.T. Clark, D.B. Hunninghake, National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association, et al.
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Circulation, (2004), 110 pp. 227-239
[13.]
R.M. Conroy, K. Pyorala, A.P. Fitzgerald, S. Sans, A. Menotti, G. De Backer, SCORE project group, et al.
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.
Eur Heart J, (2003), 24 pp. 987-1003
[14.]
J. Shepherd, G.J. Blauw, M.B. Murphy, E.L. Bollen, B.M. Buckley, S.M. Cobbe, PROSPER study group, et al.
Prospective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.
Lancet, (2002), 360 pp. 1623-1630
[15.]
Cholesterol Treatment Trialists (CTT) Collaborators.
Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90 056 participants in 14 randomised trials of statins.
Lancet, (2005), 366 pp. 1267-1278
[16.]
J.G. Robinson, B. Smith, N. Maheshwari, H. Schrott.
Peliotropic effects of satins: benefit beyond cholesterol reduction? A meta-regression analysis.
J Am Coll Cardiol, (2005), 46 pp. 1855-1862
[17.]
D.J. Jenkins, C.W. Kendall, A. Marchie, D.A. Faulkner, J.M. Wong, R. De Souza, et al.
Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein.
JAMA, (2003), 290 pp. 502-510
Este trabajo se ha realizado con la financiación obtenida con cargo a la Red de Hiperlipemias Genéticas, del Instituto Carlos III. Ministerio de Sanidad y Consumo (FIS: G03/181).
Copyright ©
2006. Sociedad Española de Cardiología